TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37012551

Group type: EXPERIMENTAL
Intervention: Lorlatinib as a single agent in children (12 months to <18 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorlatinib as a single agent in adults (≥18 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorlatinib in combination with topotecan/cyclophosphamide in children (<18 years)
Number of subjects: 0
Study: 37013442

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids/long-acting beta-agonists (ICSs/LABAs)
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonists (LAMAs)
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: ICS/LABA + LAMA
Number of subjects: 4978

Group type: COMPARATOR
Intervention: Neither ICS nor long-acting bronchodilators
Number of subjects: 4978
Study: 37013472

Group type: EXPERIMENTAL
Intervention: Propofol TIVA
Number of subjects: 90

Group type: COMPARATOR
Intervention: Inhalational anaesthesia (SEVO)
Number of subjects: 90
Study: 37013485

Group type: EXPERIMENTAL
Intervention: Digital healthcare system rehabilitation
Number of subjects: 324

Group type: COMPARATOR
Intervention: Conventional education-based rehabilitation
Number of subjects: 324
Study: 37013499

Group type: EXPERIMENTAL
Intervention: Music listening for 30 minutes before surgery, during spinal anesthesia, and for 30 minutes after surgery
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no music listening)
Number of subjects: 108
Study: 37013586

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) for 6 months, three times per week
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care plus education (CON)
Number of subjects: 58
Study: 37013610

Group type: EXPERIMENTAL
Intervention: SHR7280 (100 to 1000 mg BID)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 37013654

Group type: EXPERIMENTAL
Intervention: High density spinal cord stimulation (SCS) for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: No stimulation for 6 months (Control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patient related outcome measures
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Major cardiac adverse events
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Safety endpoints
Number of subjects: 18
Study: 37013676

Group type: EXPERIMENTAL
Intervention: Avatrombopag
Number of subjects: 0
Study: 37013954

Group type: EXPERIMENTAL
Intervention: Lenalidomide (20 mg daily from days 1 to 21 of each 28-day cycle) + Rituximab (375 mg/m2 weekly, starting on cycle 1, day 1 until cycle 2, day 1) + Venetoclax (400 mg daily at maximum tolerated dose)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lenalidomide + Rituximab + Venetoclax
Number of subjects: 28
Study: 37014057

Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline (≥ 3%)
Number of subjects: 5205
Study: 37014070

Group type: EXPERIMENTAL
Intervention: Discharge teaching intervention for older adults
Number of subjects: 30
Study: 37014289

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) sotalol loading dose
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional oral (PO) loading
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) sotalol loading
Number of subjects: 120
Study: 37014462

Group type: EXPERIMENTAL
Intervention: Facemask combined with HFNO
Number of subjects: 450

Group type: COMPARATOR
Intervention: Facemask-alone
Number of subjects: 450
Study: 37014505

Group type: EXPERIMENTAL
Intervention: MINST
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 37014515

Group type: EXPERIMENTAL
Intervention: 3-Meter Backwalk Test (3MBWT)
Number of subjects: 55
Study: 37014543

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Conception within 18 months postoperative
Number of subjects: 135

Group type: COMPARATOR
Intervention: Conception after 18 months postoperative
Number of subjects: 135
Study: 37014580

Group type: EXPERIMENTAL
Intervention: ESBL-producing E. coli carriers
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: ESBL-producing K. pneumoniae carriers
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Presence of Sellimonas intestinalis
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Campylobacter ureolyticus, Campylobacter hominis, Clostridium cluster XI, Saccharomyces sp.
Number of subjects: 255
Study: 37014668

Group type: EXPERIMENTAL
Intervention: Inferred Immune Cell Activity (iICA) hot cluster tumors
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Inferred Immune Cell Activity (iICA) warm cluster tumors
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Higher levels of tumor-infiltrating lymphocytes (TIL)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Inferred Immune Cell Activity (iICA) cluster
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Hot or warm cluster tumors
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: T-cell types inferred activity
Number of subjects: 279
Study: 37014672

Group type: EXPERIMENTAL
Intervention: Energy storing and returning prosthetic device
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Articulating prosthetic device
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Powered prosthetic device
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All 3 prosthetic devices concurrently
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Full-body gait analysis (subset of 30 participants)
Number of subjects: 100
Study: 37014673

Group type: EXPERIMENTAL
Intervention: IQOS-HTP
Number of subjects: 211

Group type: COMPARATOR
Intervention: JustFog-EC
Number of subjects: 211
Study: 37014940

Group type: EXPERIMENTAL
Intervention: Novel motivational approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37015033

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37015066

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo stretching program
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Exercise-induced vision dysfunction
Number of subjects: 99
Study: 37015244

Group type: EXPERIMENTAL
Intervention: Sparsentan 400 mg once daily
Number of subjects: 404

Group type: COMPARATOR
Intervention: Irbesartan 300 mg once daily
Number of subjects: 404
Study: 37015291

Group type: EXPERIMENTAL
Intervention: Pelvic fascia-sparing robotic-assisted radical prostatectomy (PFS-RARP)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional robotic-assisted prostatectomy (RARP)
Number of subjects: 600
Study: 37015757

Group type: EXPERIMENTAL
Intervention: Random Coefficient (RC) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: ANCOVA+LE
Number of subjects: 0

Group type: COMPARATOR
Intervention: ANCOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RC+observed (OBS)
Number of subjects: 0
Study: 37015789

Group type: EXPERIMENTAL
Intervention: Observation of violent incidents during shifts
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Observation of staff debriefing duration
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Analysis of risk factors for violent incidents
Number of subjects: 48
Study: 37015984

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 5041

Group type: COMPARATOR
Intervention: COVID-19 negative patients
Number of subjects: 5041

Group type: COMPARATOR
Intervention: Patients without a COVID-19 test
Number of subjects: 5041

Group type: EXPERIMENTAL
Intervention: COVID-positive status
Number of subjects: 5041
Study: 37015996

Group type: EXPERIMENTAL
Intervention: DIMS spectacles for 6 years (Group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: DIMS spectacles for 6 years (Group 1) and DIMS spectacles for 2 years then switched to DIMS (Group 3)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Single vision spectacles (Group 2 and Group 4)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 37016126

Group type: EXPERIMENTAL
Intervention: Oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W) with durvalumab 10 mg/kg intravenously Q2W
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Oleclumab in CRC expansion cohort
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Oleclumab in PDAC expansion cohort
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Oleclumab in NSCLC expansion cohort
Number of subjects: 192
Study: 37016181

Group type: COMPARATOR
Intervention: Work Productivity and Activity Impairment (WPAI) questionnaire
Number of subjects: 462

Group type: COMPARATOR
Intervention: Migraine Specific Quality of Life Questionnaire version 2.1 (MSQv2.1)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Monthly migraine headache days
Number of subjects: 462

Group type: COMPARATOR
Intervention: WPAI domain scores
Number of subjects: 462
Study: 37016303

Group type: EXPERIMENTAL
Intervention: Docetaxel, oxaliplatin, and S-1 (DOS regimen) followed by radical resection
Number of subjects: 73

Group type: COMPARATOR
Intervention: Chemotherapy (DOS regimen)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Docetaxel, oxaliplatin, and S-1 (DOS regimen) followed by radical resection after propensity score matching
Number of subjects: 73

Group type: COMPARATOR
Intervention: Chemotherapy (DOS regimen) after propensity score matching
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups (resection and chemotherapy)
Number of subjects: 73
Study: 37016309

Group type: EXPERIMENTAL
Intervention: Sodium polystyrene sulfonate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Polyethylene glycol (nonspecific laxative)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 37016326

Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg oral) + Misoprostol (25 µg vaginal)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Misoprostol (25 µg vaginal) + Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Propranolol + Misoprostol
Number of subjects: 128
Study: 37016357

Group type: EXPERIMENTAL
Intervention: Outdoor time (up to 2.3 hours per day)
Number of subjects: 3291

Group type: EXPERIMENTAL
Intervention: Daily sleep duration
Number of subjects: 3291

Group type: EXPERIMENTAL
Intervention: Out-of-school learning time
Number of subjects: 3291

Group type: EXPERIMENTAL
Intervention: Outdoor time (exceeding 2.3 hours per day)
Number of subjects: 3291

Group type: EXPERIMENTAL
Intervention: Outdoor time, sleep duration, and out-of-school learning time
Number of subjects: 3291
Study: 37016372

Group type: EXPERIMENTAL
Intervention: Healthy School Start Plus (HSSP) intervention
Number of subjects: 20
Study: 37016392

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) - weekly single-day courses
Number of subjects: 824

Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP) - monthly single-day courses
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 824
Study: 37016394

Group type: EXPERIMENTAL
Intervention: MOUD with adjunctive use of OptiMAT (MOUD+OptiMAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MOUD without OptiMAT (MOUD-only)
Number of subjects: 0
Study: 37016454

Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: High tibial osteotomy (HTO)
Number of subjects: 100
Study: 37016469

Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of 1-19 steps
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of 20-39 steps
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of 40-59 steps
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of 60-79 steps
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of 80-99 steps
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Natural walking at intensity levels of ≥100 steps
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Longest daily sustained walking bout at 1-19 steps
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Bouts lasting 20 minutes and greater
Number of subjects: 82
Study: 37016622

Group type: EXPERIMENTAL
Intervention: SF-36 physical component summary (PCS)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: SF-36 mental component summary (MCS)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: EQ-VAS
Number of subjects: 276
Study: 37016808

Group type: EXPERIMENTAL
Intervention: Acetabular cups fixated with 1 screw
Number of subjects: 68

Group type: COMPARATOR
Intervention: Acetabular cups fixated with no screws
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Acetabular cups fixated with 2 screws
Number of subjects: 68
Study: 37016906

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg oral daily and bevacizumab 15 mg/kg intravenously on day 1, repeated every 21 days until disease progression, intolerable toxicity, or death
Number of subjects: 52
Study: 37017254

Group type: EXPERIMENTAL
Intervention: Belimumab plus standard therapy (ST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (ST) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belimumab plus ST
Number of subjects: 0
Study: 37017401

Group type: EXPERIMENTAL
Intervention: Relaxation intervention (four relaxation sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation intervention
Number of subjects: 0
Study: 37017468

Group type: EXPERIMENTAL
Intervention: Adaptive Bolus Calculator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study: 37017470

Group type: EXPERIMENTAL
Intervention: Increased derived time in range (dTIR)
Number of subjects: 0
Study: 37017631

Group type: EXPERIMENTAL
Intervention: Molnupiravir (MOV)
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1313
Study: 37017634

Group type: EXPERIMENTAL
Intervention: Cough stimulation system (CSS)
Number of subjects: 15
Study: 37017737

Group type: EXPERIMENTAL
Intervention: Gantenerumab
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 37017765

Group type: EXPERIMENTAL
Intervention: Whole wheat bread enriched with hydroxytyrosol (HTB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional whole wheat bread (WWB)
Number of subjects: 60
Study: 37017900

Group type: EXPERIMENTAL
Intervention: Preoperative quantitative flow ratio (QFR) assessment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Non-functional bypass grafts
Number of subjects: 54
Study: 37017967

Group type: EXPERIMENTAL
Intervention: Implementation Facilitation (IF)
Number of subjects: 756
Study: 37018024

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum NCC3001 (probiotic) during pregnancy and postpartum (from 28-32 weeks' gestation until 12 weeks after delivery)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum NCC3001 (probiotic) postpartum only (from birth until 12 weeks after delivery)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 180
Study: 37018064

Group type: EXPERIMENTAL
Intervention: Vorinostat (oral administration)
Number of subjects: 7
Study: 37018188

Group type: EXPERIMENTAL
Intervention: Abrupt glucocorticoid stop
Number of subjects: 573

Group type: COMPARATOR
Intervention: Tapering doses of prednisone
Number of subjects: 573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: ACTH-test
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Cumulative glucocorticoid doses
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Signs and symptoms of hypocortisolism
Number of subjects: 573
Study: 37018234

Group type: EXPERIMENTAL
Intervention: Busulfan treatment in lymphoblastoid cell lines (LCLs)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Combination of expression experiment and WES data analysis
Number of subjects: 87
Study: 37018415

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR)-T cells enriched in memory T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard CAR-T cells (not enriched in memory T cells)
Number of subjects: 0
Study: 37018468

Group type: EXPERIMENTAL
Intervention: RSVpreF vaccine (120 μg)
Number of subjects: 34284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34284
Study: 37018474

Group type: EXPERIMENTAL
Intervention: Bivalent RSV prefusion F protein-based vaccine (120 μg, single intramuscular injection)
Number of subjects: 3682
Study: 37018492

Group type: EXPERIMENTAL
Intervention: GD2-CART01
Number of subjects: 27
Study: 37018493

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 501

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 501
Study: 37018649

Group type: EXPERIMENTAL
Intervention: Fluorouracil and folinic acid maintenance therapy with panitumumab
Number of subjects: 377

Group type: COMPARATOR
Intervention: Fluorouracil and folinic acid maintenance therapy without panitumumab
Number of subjects: 377
Study: 37018790

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local standard treatment alone
Number of subjects: 0
Study: 37018802

Group type: EXPERIMENTAL
Intervention: EHP with Efferon LPS
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (conventional protocols without EHP)
Number of subjects: 58
Study: 37018848

Group type: EXPERIMENTAL
Intervention: Combined exercise and BCAA supplementation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Exercise-only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BCAA supplementation-only
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 37018968

Group type: EXPERIMENTAL
Intervention: Vigileo/FloTrac-guided hydration
Number of subjects: 344

Group type: COMPARATOR
Intervention: General hydration (control)
Number of subjects: 344
Study: 37019044

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus a newly initiated oral antidepressant (ESK+AD)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Newly initiated oral antidepressant plus placebo nasal spray (AD+PBO)
Number of subjects: 518
Study: 37019077

Group type: EXPERIMENTAL
Intervention: ARB dose >0%-25%
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: ARB dose >25%
Number of subjects: 4800

Group type: COMPARATOR
Intervention: ARB dose ≤25%
Number of subjects: 4800

Group type: COMPARATOR
Intervention: No ARB
Number of subjects: 4800
Study: 37019180

Group type: EXPERIMENTAL
Intervention: Low-free sugar diet (LFSD)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual diet + educational materials
Number of subjects: 140
Study: 37019195

Group type: EXPERIMENTAL
Intervention: WatchPAT home sleep testing (HST) for OSA
Number of subjects: 38
Study: 37019309

Group type: EXPERIMENTAL
Intervention: Dual-mobility bearings (DM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Large femoral heads (≥36 mm)
Number of subjects: 146
Study: 37019334

Group type: EXPERIMENTAL
Intervention: High dose erythropoietin (Epo)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 37019352

Group type: EXPERIMENTAL
Intervention: Head-to-pelvis sudden death CT (SDCT) scan within 6 hours of hospital arrival
Number of subjects: 247

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 247
Study: 37019355

Group type: EXPERIMENTAL
Intervention: Prediction model PLUS-M for lung cancer staging-mediastinal metastasis
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Prediction model PLUS-E for mediastinal metastasis detection by EBUS-TBNA
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Validation cohort for PLUS-M
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Validation cohort for PLUS-E
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 589
Study: 37019361

Group type: EXPERIMENTAL
Intervention: EAT-Lancet reference diet adherence (measured by EAT-Lancet Diet Index - ELD-I)
Number of subjects: 98465

Group type: EXPERIMENTAL
Intervention: EAT-Lancet reference diet adherence (measured by ELD-I)
Number of subjects: 98465
Study: 37019367

Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab with Definitive Radiation Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37019443

Group type: EXPERIMENTAL
Intervention: 1 g IV tranexamic acid (TXA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1 g IM tranexamic acid (TXA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4 g oral tranexamic acid (TXA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No TXA (Control)
Number of subjects: 120
Study: 37019445

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study: 37019471

Group type: EXPERIMENTAL
Intervention: CF33-hNIS-antiPDL1 (intraperitoneal treatment)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CF33-OVs (intraperitoneal treatment)
Number of subjects: 6
Study: 37019486

Group type: EXPERIMENTAL
Intervention: biparametric MRI (bpMRI)
Number of subjects: 500

Group type: COMPARATOR
Intervention: multiparametric MRI (mpMRI)
Number of subjects: 500
Study: 37019487

Group type: EXPERIMENTAL
Intervention: ACHRU-CPP intervention (6-month self-management program including home and phone visits, care coordination, system navigation support, caregiver support, and group wellness sessions)
Number of subjects: 45
Study: 37019491

Group type: EXPERIMENTAL
Intervention: Wireless physical activity monitor (WPAM)
Number of subjects: 80
Study: 37019582

Group type: EXPERIMENTAL
Intervention: Prolonged moderate-intensity exercise (30, 40, or 50 km/d for 4 consecutive days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prolonged moderate-intensity exercise
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Leukocyte CoQ10 levels
Number of subjects: 100
Study: 37019619

Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPARγ/VEGF-A-mediated TME immunosuppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase II trial of pembrolizumab (NCT03419481)
Number of subjects: 0